Letter to the editor: lansoprazole interferes with fungal respiration and acts synergistically with amphotericin B against multidrug-resistant
Amphotericin B
Antifungal Resistance
Candida auris
Lansoprazole
Proton Pump Inhibitor
Journal
Emerging microbes & infections
ISSN: 2222-1751
Titre abrégé: Emerg Microbes Infect
Pays: United States
ID NLM: 101594885
Informations de publication
Date de publication:
Dec 2024
Dec 2024
Historique:
medline:
16
6
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
ppublish
Résumé
The study investigates the potential of lansoprazole, a proton pump inhibitor, to interfere with fungal respiration and enhance the antifungal activity of amphotericin B against multidrug-resistant Candida auris. The authors administered lansoprazole at concentrations significantly higher than typical therapeutic doses, which demonstrated promising results but also raised concerns about potential toxicity. We suggest incorporating a control group, monitoring toxicity indicators, performing pathological examinations, and conducting cellular assays to improve the study's rigor and reliability. We also highlight the need for further research into the mechanisms of lansoprazole's antifungal activity, its long-term effects on amphotericin B resistance, and potential drug-drug interactions with amphotericin B. Addressing these concerns is crucial for the clinical translation of lansoprazole as an adjuvant to amphotericin B.
Identifiants
pubmed: 38742537
doi: 10.1080/22221751.2024.2356144
doi:
Substances chimiques
Lansoprazole
0K5C5T2QPG
Amphotericin B
7XU7A7DROE
Antifungal Agents
0
Proton Pump Inhibitors
0
Types de publication
Letter
Journal Article
Langues
eng
Sous-ensembles de citation
IM